Since 2013, DMF has been approved by the U.S. Food and Drug Administration (FDA) as a treatment option for adults with RRMS, and part of its beneficial effects on MS have been hypothesized to occur via Nrf2 activation [91,92,93]. Here, NFE2L2 is linked to myeloid sarcoma.